Lantheus Holdings (STU:0L8) Short Interest


STU:0L8 Lantheus Holdings Inc STU:0L8
87 GF Score
Price €96.50
GF Value €79.89
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lantheus Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:0L8 vs LQDA, HIMS, AMRX: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantheus Holdings Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Short Interest falls into.


STU:0L8
87GF Score
Lantheus Holdings Inc STU:0L8
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lantheus Holdings (STU:0L8) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of €96.50 is trading 20.8% above its estimated GF Value™ of €79.89. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for STU:0L8:

  • Short Interest:
  • GF Value™: €79.89 vs. price of €96.50 (20.8% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lantheus Holdings Business Description

Other Exchanges LNTH:USA1LNTH:Italy
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
87GF Score

Get the complete analysis for STU:0L8

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€96.50
Price
€79.89
GF Value